How are you feeling today? Keep up to date on news and stories related to health care here!
—Portfolio helps maximize investment in LabVantage LIMS; offers tailored success plans for each customer— —Up to 75% reduction in testing efforts, 50% reduction in configuration efforts, fewer support tickets, and improved system performance— SOMERSET, N.J. — (BUSINESS WIRE) —
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union RAHWAY, N.J. — (BUSINESS WIRE) — $MRK #MRK — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, on Tuesday
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and
Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) CR rates were: 82.8% for patients
Surpassing $10M in revenue, Pulsetto processed nearly 40,000 orders in 2024. The company helped over 100,000 users manage stress and emotional well-being, and gained worldwide recognition as a frontrunner in longevity and health optimization. — Nearly half of the global
Zoetis plans to immediately implement updated label based on U.S. post-approval experience with Librela Company remains confident in the safety and effectiveness of Librela and reaffirms its commitment to supporting veterinarians and pet owners in helping dogs with OA live with less
Now accepting applications for 2025 grants to accelerate innovation in tissue transplantation EDISON, N.J. — (BUSINESS WIRE) — MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, has awarded
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU to an earlier HR positive treatment setting and broadens the patient
Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up Late-breaking data presented in oral session at the 2025